1. Medtech Insight
  2. >>Business

Cochlear Combines With Sensorion To Explore Hearing-Loss Treatments

 
• By Catherine Longworth

Cochlear Ltd. has formed an alliance with French biotech company Sensorion to explore if a combination drug/hearing implant can improve the treatment of hearing loss. The collaboration moves Cochlear outside of its device field and could see it obtain a global license for Sensorion's SENS-401 drug candidate.

Cochlear Ltd. has entered an agreement to collaborate with French clinical stage biotech company Sensorion to explore if a combination drug/hearing implant can improve the treatment of hearing loss. The preclinical combination studies will evaluate Sensorion's drug candidate SENS-401 therapeutic effect on hearing outcomes achieved with Cochlear’s implantable devices.

The collaboration sends a strong signal to the market that Cochlear intends to maintain its leading position

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.

Thousands Of Cardiac Digital Twins Reveal Novel Connections With Mental Health

 
• By Natasha Barrow

King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By Shubham Singh

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

More from Medtech Insight